Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Icosavax, Inc.
Initial public offering momentum decelerated as stock prices declined last year, but even with lower valuations making M&A more attractive, the IPO market this year is expected to be active.
Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
Swiss biotech Numab Therapeutics has raised an oversubscribed series C financing of CHF100m to accelerate the development of its multispecific antibodies, from investors attracted by the company’s thoughtful approach to developing its technology.